
|Articles|December 12, 2012
Zytiga now available for late-stage prostate cancer
FDA expanded the approved use of abiraterone acetate (Zytiga, Janssen Bioech) to treat men with late-stage castration-resistant prostate cancer prior to receiving chemotherapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Executive Order Calls for Realignment of Childhood Vaccines
2
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
3
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
4
Q&A: Pharmacists Can Address ADA Standards Across All Settings
5





























































